BIOCRATES LIFE SCIENCES AG

BIOCRATES LIFE SCIENCES AG specializes in targeted metabolomics research and the development of precision diagnostic reagent kits for human biological samples. Their core capabilities center on advanced mass spectrometry-based analytical platforms, including quantitative profiling of plasma, tissue, and other biofluids using proprietary MXP QUANT assay technologies. The contractor delivers end-to-end metabolomic analysis—spanning assay design, high-throughput sample processing, data acquisition, and bioinformatics reporting—enabling biomarker discovery and metabolic pathway characterization in clinical and translational research settings. Key differentiators include validated protocols for complex human specimens, robust data standardization, and integration of analytical instrumentation such as SCIEX platforms, positioning them as a niche provider of reproducible, clinically relevant metabolomic solutions. The contractor maintains a consistent and exclusive relationship with the Department of Health and Human Services, delivering research and diagnostic services primarily to support public health and biomedical innovation initiatives. Work includes both fundamental research into neurological and metabolic disorders and the production of standardized in-vitro diagnostic reagents, indicating a dual role as both a research partner and a regulated diagnostic reagent supplier. Their primary industry focus is on research and development in biotechnology (NAICS 541714), with supplemental activity in in-vitro diagnostic substance manufacturing (NAICS 325413). This reflects a strategic positioning at the intersection of academic research and regulated diagnostics, serving the growing demand for quantitative metabolomic tools in precision medicine and clinical trials. BIOCRATES LIFE SCIENCES AG is structured as a foreign entity headquartered in Innsbruck, with no U.S.-based certifications on record. Despite lacking formal government certifications, their repeated engagement with HHS underscores their technical credibility and alignment with federal research priorities in metabolomics and diagnostic development.